SEC Filings
Immunic Expects $132 Million To Fund Operations Into Late 2027 Ahead Of MS Results
December trial results will determine whether the company pursues its planned U.S. drug-approval application in mid-2027.
Immunic (IMUX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
December trial results will determine whether the company pursues its planned U.S. drug-approval application in mid-2027.
SEC Filings
The drug developer’s most advanced candidate is in late-stage testing for relapsing multiple sclerosis.